# Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

> **NCT03190265** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 61 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** GVAX Pancreas Vaccine
- **DRUG:** CRS-207
- **DRUG:** CRS-207

## Key facts

- **NCT ID:** NCT03190265
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-14
- **Primary completion:** 2022-08-03
- **Final completion:** 2023-08-23
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-08-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03190265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03190265, "Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03190265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*